Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference

Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York.

Details of the event are as follows:

Date: Thursday, June 8, 2023

Time: 10:30 a.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

[email protected]

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

[email protected]

KEYWORDS: United States North America Massachusetts California New York

INDUSTRY KEYWORDS: Biotechnology Health Oncology

MEDIA:

Logo
Logo

MindMed to Participate at Upcoming Investor Conferences

MindMed to Participate at Upcoming Investor Conferences

NEW YORK–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

  • BIO International Convention

    • Format: Investor Presentation

    • Date and Time: Monday, June 5, 2023 at 3:30 pm EDT

  • Jefferies Healthcare Conference

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Resources website for up to 90 days following each event.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media & Investor Inquiries, please contact:

Maxim Jacobs, CFA

Vice President, Investor Relations and Corporate Communications

Mind Medicine (MindMed) Inc.

[email protected]

[email protected]

KEYWORDS: Europe United States United Kingdom North America New York

INDUSTRY KEYWORDS: Biotechnology Neurology Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo

PlugShare Achieves Milestone of More Than 6.5 Million Check-Ins as Global EV Adoption Grows

PlugShare Achieves Milestone of More Than 6.5 Million Check-Ins as Global EV Adoption Grows

In less than one year, the PlugShare EV community has grown from 2.5 million to more than 3.5 million registered users

EL SEGUNDO, Calif.–(BUSINESS WIRE)–PlugShare, the world’s leading electric vehicle (EV) community and a part of the EVgo Inc. (NASDAQ: EVGO) family since mid-2021, celebrates the platform exceeding 6.5 million user check-ins. The PlugShare user base also grew more than 40% in the last year, adding 1 million new users to reach over 3.5 million registered users around the globe. This rapidly growing community of EV drivers provides up-to-date, helpful information on over 750,000 charging stations listed on the platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005246/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

“PlugShare continues to be the largest consumer tech platform for EV drivers. The user growth and engagement experienced by the PlugShare app reflects both the momentum behind EV adoption as well as the invaluable real-time EV charging data, driver reviews, features and tools that PlugShare offers to enable a seamless EV charging experience,” said Tanvi Chaturvedi, CRO of EVgo. “At EVgo, we know that as new EV drivers continue to hit the road, a consistent and convenient charging experience is critical. The drivers who utilize the PlugShare platform not only help create a strong EV community both here in the U.S. and around the world, but the information they provide also complements our efforts to monitor our network to ensure we’re delivering a best-in-class customer experience.”

Globally, EVs are seeing exponential growth—in 2022, EVs accounted for 14% of all new cars sold, up from roughly 9% in 2021 and less than 5% in 2020, according to the International Energy Agency. The market growth is matched by the continuing expansion of the PlugShare community. As the world’s largest community of EV drivers, the PlugShare app is available in nearly 30 different languages. By sharing their charging experiences through check-ins on the platform, users help fellow EV drivers stay informed and can offer real-time updates about charging stations around the world.

With millions of crowd-sourced check-ins and over 775,000 photos uploaded by drivers, PlugShare enables users to review their personal charging experiences, access trip planning resources, and learn what to expect at different charging locations. Using a rating system known as a PlugScore®, PlugShare combines user reviews to produce a score that reflects recent charging experiences that drivers have had at a particular station.

PlugShare is available on the web and for download on iOS, Apple Watch and Android. Users that are registered with PlugShare can also take advantage of Pay with PlugShare to unlock the ability to pay for and activate sessions on public charging stations directly from within the app. PlugShare enables users to filter results by their preferred network, charging speed or connector type (CCS, CHAdeMO, J-1772, Tesla), and easily locate and navigate to chargers.

For more information and to find the location of EV chargers within the EVgo charging network, visit www.evgo.com and www.plugshare.com.

About PlugShare

Based in El Segundo CA, PlugShare maintains the most comprehensive census of EV infrastructure in the world. The PlugShare app is available for iOS, Android, including in-dash for Android Automotive OS and open-source Android OS, and online. PlugShare also provides sophisticated data tools, reports, custom consulting and comprehensive research on EVs for automakers, utilities, charging networks, government and the rest of the EV industry. It operates the world’s largest EV driver survey research panel, PlugInsights, now with over 100,000 members and PlugShare is the most popular EV driver app globally.

About EVgo

EVgo (Nasdaq: EVGO) is a leader in charging solutions, building and operating the infrastructure and tools needed to expedite the mass adoption of electric vehicles for individual drivers, rideshare and commercial fleets, and businesses. Since 2019, EVgo has purchased renewable energy certificates to match the electricity that powers its network. As one of the nation’s largest public fast charging networks, EVgo’s owned and operated charging network includes around 900 fast charging locations, 60 metropolitan areas and 30 states. EVgo continues to add more DC fast charging locations across the U.S., including stations built through EVgo eXtend™, its white label service offering. EVgo is accelerating transportation electrification through partnerships with automakers, fleet and rideshare operators, retail hosts such as grocery stores, shopping centers, and gas stations, policy leaders, and other organizations. With a rapidly growing network, robust software products and unique service offerings for drivers and partners including EVgo Optima™, EVgo Inside™, EVgo Rewards™, and Autocharge+, EVgo enables a world-class charging experience where drivers live, work, travel and play.

For Investors: [email protected]

For Media: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Other Energy Alternative Energy EV/Electric Vehicles Energy Automotive Technology General Automotive Other Technology

MEDIA:

Logo
Logo
Photo
Photo
(Graphic: Business Wire)

CareDx to Participate in Upcoming Investor Conferences

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.–(BUSINESS WIRE)–
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.

CareDx’s management is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023, at 8:00 AM PT / 11:00 AM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com.

CareDx’s management will also be presenting at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13th, 2023, at 4:40 PM PT / 7:40 PM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CareDx, Inc.

Media Relations

Anna Czene

818-731-2203

[email protected]

Investor Relations

Greg Chodaczek

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: General Health Health Technology Health Surgery

MEDIA:

Logo
Logo

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results for the three months ended March 31, 2023.

Clinical and Corporate Development Highlights Include:

NAMODENOSON

Oncology

Pivotal Phase 3 Liver Cancer Study—Can-Fite’s ongoing pivotal Phase 3 liver cancer study is designed to assess Namodenoson in the treatment of patients with advanced hepatocellular carcinoma (HCC) and underlying Child Pugh B7 (CPB7) who have not responded to 1 or 2 other lines of therapy. The primary endpoint is overall survival. An interim analysis will be performed.

During the first quarter, a study titled “Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects” was published in the peer-reviewed journal Purinergic Signalling.

Phase 2a Pancreatic Cancer Study—Can-Fite is preparing for an open-label Phase 2 exploratory trial to assess the safety and efficacy of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy. Safety and efficacy endpoints including objective response, progression-free survival, duration of response, disease control, and overall survival will be monitored. The study will be conducted by Dr. Salomon Stemmer, an oncology key opinion leader and Professor at the Institute of Oncology, Rabin Medical Center, Israel. In pre-clinical studies, Namodenoson had a significant anti-cancer effect in pancreatic carcinoma as a monotherapy and an additive effect when combined with gemcitabine, the standard-of-care chemotherapy for pancreatic cancer. The mechanism of action entails de-regulation of the Wnt signal transduction pathway, a key modulator of pancreatic carcinoma cell growth.

Can-Fite filed a patent application that covers the use of Namodenoson for the treatment of pancreatic cancer. Moreover, Can-Fite’s pancreatic cancer program received recognition from ASCO when its study titled “Effects of Namodenoson on Pancreatic Carcinoma: Preclinical Evidence” was published in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings.

Pancreatic cancer is an unmet medical need. According to the American Society of Clinical Oncology (ASCO), in 2020, an estimated 496,000 people were diagnosed with pancreatic cancer globally and an estimated 466,000 died from the disease. The 5-year survival rate for people with pancreatic cancer in the U.S. is 11%. Acumen Research estimates the global pancreatic cancer therapeutics market was valued at approximately $3.6 billion in 2021 and is projected to grow to approximately $6.6 billion by 2030.

Liver Diseases

Phase 2b NASH Study—A Phase 2b NASH study is currently ongoing to evaluate Namodenoson’s efficacy as compared to placebo, determined by a histological endpoint. Namodenoson met its primary endpoint of reducing liver fat, inhibiting fibrosis, and demonstrating an anti-inflammatory effect in a prior Phase 2a NASH study.

Compassionate Use in Patients with Decompensated Liver Cirrhosis—Based on data showing that Namodenoson has liver protective effects, Namodenoson is now given to patients with decompensated cirrhosis, an advanced form of cirrhosis associated with liver failure for which there are no therapeutic options other than liver transplantation. Patients will be treated with Namodenoson at the Soroka Medical Center in Israel under compassionate use.

Decompensated cirrhosis is an acute deterioration in liver function in patients with cirrhosis, characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal hemorrhage. This is an unmet medical need and there is no therapeutic approach that has shown efficacy in slowing disease progression. An estimated 10.6 million people globally had decompensated cirrhosis in 2017, with few treatment options available aside from liver transplants if the decompensated cirrhosis has reached an advanced stage. The treatment of liver cirrhosis in the U.S. is estimated to become an approximately $15 billion market by 2030.

PICLIDENOSON

Green Light from EMA for a Pivotal Phase 3 Psoriasis Study—The European Medicines Agency (EMA) gave Can-Fite a positive opinion on its registration plan for a pivotal Phase 3 clinical trial for Piclidenoson in the treatment of moderate to severe psoriasis. The pivotal study and the safety of the 3 mg twice daily dose of Piclidenoson are accepted by the agency.

Can-Fite has submitted a comparable data package to the U.S. Food and Drug Administration (FDA) and expects a similar response.

Corporate Developments

New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization—Effective June 30, 2023, executive changes go into effect to support the Company’s continued success. Motti Farbstein will lead Can-Fite as Chief Executive Officer and continue to serve as its Chief Financial Officer. Dr. Pnina Fishman, Can-Fite’s Scientific Founder, will move from her position as CEO to become Executive Chairman of the Board as well as continuing to serve as Chief Scientific Officer.

Raised $7.5 Million—In January 2023, Can-Fite raised $7.5 million through a concurrent registered direct offering and private placement. The Company’s cash and equivalents on March 31, 2023 was $12.4 million and is expected to cover all clinical development programs and general and administrative expenses for more than a year from the date of this press release.

“During 2023 we plan to increase our efforts towards establishing additional distribution deals and partnerships. We continue to make progress with our two main indications, liver cancer and psoriasis, as we open additional avenues with niche indications based on evidence of the efficacy and safety of our drugs,” stated Can-Fite CEO Dr. Pnina Fishman.

Financial Results

Revenues for the three months ended March 31, 2023 were $0.19 million, a decrease of $0.01 million, or 4.40%, compared to $0.20 million for the three months ended March 31, 2022. The decrease in revenues is considered to be immaterial.

Research and development expenses for the three months ended March 31, 2023 were $2.06 million, an increase of $0.24 million, or 13.17%, compared to $1.82 million for the three months ended March 31, 2022. Research and development expenses for the first quarter of 2023 comprised primarily of expenses associated with the completion of the Phase 3 study of Piclidenoson for the treatment of psoriasis and two ongoing studies for Namodenoson, a Phase 3 study in the treatment of advanced liver cancer and a Phase 2b study for NASH. The increase is primarily due to an increase in expenses associated with Namodenoson.

General and administrative expenses for the three months ended March 31, 2023 were $0.84 million an increase of $0.09 million, or 12.33%, compared to $0.75 million for the three months ended March 31, 2022. The increase is primarily due to the increase in travel expenses and increase in accrued bonuses to the Company’s employees. We expect that general and administrative expenses will remain at the same level through 2023.

Financial income, net for the three months ended March 31, 2023 was $0.16 million compared to finance expense, net of $0.06 million for the three months ended March 31, 2022. The increase in financial income, net was mainly due to exchange rate differences which in 2023 was recorded as income and in 2022 was recorded as expense and revaluation of our short-term investment which in 2023 was recorded as income and in 2022 was recorded as expense.

Net loss for the three months ended March 31, 2023 was $2.55 million compared with a net loss of $2.43 million for the three months ended March 31, 2022. The increase in net loss for the three months ended March 31, 2023 was primarily attributable to an increase in research and development expenses which was partly offset by an increase in finance income, net.

As of March 31, 2023, Can-Fite had cash and cash equivalents and short term deposits of $12.4 million as compared to $7.98 million at December 31, 2022. The increase in cash during the three months ended March 31, 2023 is due to the issuance of share capital and warrants which was offset by ongoing operations of the Company.

The Company’s consolidated financial results for the three months ended March 31, 2023 are presented in accordance with US GAAP Reporting Standards. 

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except for share and per share data)

 

 

March 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

Unaudited

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,264

 

 

$

2,978

 

Short term deposit

 

 

11,135

 

 

 

5,001

 

Prepaid expenses and other current assets

 

 

962

 

 

 

1,170

 

Short-term investment

 

 

18

 

 

 

8

 

 

 

 

 

 

 

 

 

 

Total current assets

 

 

13,379

 

 

 

9,157

 

 

 

 

 

 

 

 

 

 

NON-CURRENT ASSETS:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease right of use assets

70

84

Property, plant and equipment, net

 

 

40

 

 

 

42

 

 

 

 

 

 

 

 

 

 

Total non-current assets

 

 

110

 

 

 

126

 

 

 

 

 

 

 

 

 

 

Total assets

 

$

13,489

 

 

$

9,283

 

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except for share and per share data)

 

 

March 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

Unaudited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade payables

 

$

963

 

 

$

896

 

Current maturity of operating lease liability

42

48

Deferred revenues

 

 

783

 

 

 

783

 

Other accounts payable

 

 

1,103

 

 

 

775

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

 

2,891

 

 

 

2,502

 

 

 

 

 

 

 

 

 

 

NON-CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long – term operating lease liability

6

14

Deferred revenues

 

 

2,099

 

 

 

2,295

 

 

 

 

 

 

 

 

 

 

Total long-term liabilities

 

 

2,105

 

 

 

2,309

 

 

CONTIGENT LIABILITIES AND COMMITMENTS

 

 

 

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ordinary shares of no-par value – Authorized: 5,000,000,000 shares at March 31, 2023 and December 31, 2022; Issued and outstanding: 1,224,837,393 and 815,746,293 shares as of March 31, 2023 and December 31, 2022

 

 

 

 

 

 

Additional paid-in capital

 

 

160,763

 

 

 

154,192

 

Accumulated other comprehensive income

 

 

1,127

 

 

 

1,127

 

Accumulated deficit

 

 

(153,397

)

 

 

(150,847

)

 

 

 

 

 

 

 

Total equity

 

 

8,493

 

 

 

4,472

 

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

$

13,489

 

 

$

2,983

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except for share and per share data)

 

 

Three months ended

March 31,

 

 

 

2023

 

 

2022

 

 

 

Unaudited

 

 

 

 

 

 

 

 

Revenues

 

$

196

 

$

205

 

 

 

 

 

 

 

Research and development expenses

 

 

(2,061

)

 

 

(1,821

)

General and administrative expenses

 

 

(847

)

 

 

(754

)

 

 

 

 

 

 

Operating loss

 

 

(2,712

)

 

 

(2,370

)

 

 

 

 

 

 

 

Total financial income (expense), net

 

 

162

 

 

(64)

 

 

 

 

 

 

Net loss attributed to ordinary shareholders

 

 

(2,550

)

 

 

(2,434

)

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

 

 

(0.00

)

 

 

(0.00

)

 

Weighted average number of ordinary shares used in computing basic and diluted net loss per share

1,178,872,101

815,746,293

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s anti-inflammatory drug Piclidenoson reported topline results in a Phase 3 trial for psoriasis and is expected to commence a pivotal Phase 3. Can-Fite’s cancer and liver drug, Namodenoson, is being evaluated in a Phase 2b trial for the treatment of non-alcoholic steatohepatitis (NASH), enrollment is expected to commence in a Phase 3 trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 30, 2023 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Can-Fite BioPharma

Motti Farbstein

[email protected]

+972-3-9241114

KEYWORDS: New York United States North America Israel Middle East

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Ingersoll Rand to Participate at the Deutsche Bank Global Industrials, Materials & Building Products Conference

Ingersoll Rand to Participate at the Deutsche Bank Global Industrials, Materials & Building Products Conference

DAVIDSON, N.C.–(BUSINESS WIRE)–
Ingersoll Rand Inc., (NYSE: IR) a global provider of mission-critical flow creation and industrial solutions, announced that Vik Kini, Chief Financial Officer, and Matthew Fort, Vice President, Investor Relations, will participate in a fireside chat at the Deutsche Bank 14th Annual Global Industrials, Materials & Building Products Conference on Wednesday, June 7, 2023 at 8:40 AM Eastern time.

A real-time audio webcast of the fireside chat can be accessed via the Events and Presentations section of the Ingersoll Rand Investor Relations website here. A replay of the webcast will be available after conclusion of the fireside chat and can be accessed on the Ingersoll Rand Investor Relations website.

About Ingersoll Rand Inc.

Ingersoll Rand Inc. (NYSE:IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to helping make life better for our employees, customers and communities. Customers lean on us for our technology-driven excellence in mission-critical flow creation and industrial solutions across 40+ respected brands where our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity and efficiency. For more information, visit www.IRCO.com.

Investor Relations:

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Machine Tools, Metalworking & Metallurgy Engineering HVAC Manufacturing Other Manufacturing Machinery

MEDIA:

Logo
Logo

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the following investor conferences in June 2023:

Company executives will take part in a fireside chat at the 2023 Jefferies Healthcare Conference in New York, New York on June 8, 2023. They will answer questions about the company at 9:00 a.m. ET.

Bristol Myers Squibb executives will also participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023, in Dana Point, California. They will answer questions about the company at 8:40 a.m. PT/11:40 a.m. ET.

Investors and the general public are invited to listen to a live webcast of both sessions during their respective times at http://investor.bms.com. An archived edition of each session will be available later the same day it occurs.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Bristol Myers Squibb

Media:

[email protected]

Investor Relations:

[email protected]

KEYWORDS: California New York United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

Macy’s, Inc. Reports First Quarter 2023 Results

Macy’s, Inc. Reports First Quarter 2023 Results

Net sales of $5 billion a decline of 7% year-over-year; merchandise inventories down 7%

Diluted EPS of $0.56 and Adjusted Diluted EPS of $0.56

$200 million of incremental cost savings expected to be realized in fiscal 2023

Adjusts full-year sales and earnings guidance

NEW YORK–(BUSINESS WIRE)–
Macy’s, Inc. (NYSE: M) today reported financial results for the first quarter of 2023 and updated its annual guidance.

“During the first quarter, we delivered a solid beat on our gross margin rate and bottom line expectations enabled by our disciplined teams, strength of our inventory management and operational efficiencies. We planned the year assuming that the economic health of the consumer would be challenged, but starting in late March, demand trends weakened further in our discretionary categories,” said Jeff Gennette, chairman and chief executive officer of Macy’s, Inc.

“We have moved quickly to take the appropriate actions to meet current consumer demand and manage our expenses. Our revised guidance reflects incremental clearance markdowns to address excess spring seasonal merchandise in the second quarter, along with adjustments to the category composition and inventory levels in the back half of the year. Supported by our solid foundation of financial health, we remain focused on strengthening our core business and advancing our five growth vectors – which we believe will drive sustainable and profitable sales growth in the future,” continued Gennette.

First Quarter Highlights

Comparisons are to the first quarter of 2022 unless noted otherwise. Comparisons to 2019 are provided, where appropriate, to benchmark performance. Please refer to note 2 within the financial tables regarding reclassifications of certain prior year metrics.

  • Diluted earnings per share of $0.56 and Adjusted diluted earnings per share of $0.56.
    • This compares to diluted earnings per share of $0.98 and Adjusted diluted earnings per share of $1.08 in the first quarter of 2022.
  • Net sales of $5 billion, down 7% versus the first quarter of 2022.
    • Brick-and-mortar sales decreased 6% versus the first quarter of 2022.

    • Digital sales decreased 8% versus the first quarter of 2022.
  • Comparable sales down 7.9% on an owned basis and down 7.2% on an owned-plus-licensed basis.

  • Highlights of the company’s nameplates include:
    • Macy’s comparable sales were down 8.7% on an owned basis and down 7.9%, on an owned-plus-licensed basis.
      • 42.2 million active customers shopped the Macy’s brand, on a trailing twelve-month basis.

      • Star Rewards program members made up approximately 70% of Macy’s brand comparable owned-plus-licensed sales on a trailing twelve-month basis, up approximately 1 percentage point versus the prior year.

      • The nameplate saw strength in beauty, particularly fragrances, men’s tailored, women’s career sportswear and off-price with Backstage.

    • Bloomingdale’s comparable sales on an owned basis were down 3.9% and on an owned-plus-licensed basis were down 4.3%.
      • 4.1 million active customers shopped the Bloomingdale’s brand, on a trailing twelve-month basis.

      • The nameplate saw strength across beauty, particularly fragrances, women’s and men’s contemporary apparel, housewares and the outlet locations.

    • Bluemercury comparable sales were up 4.3% on an owned basis.
      • Approximately 676,000 active customers shopped the Bluemercury brand, on a trailing twelve-month basis.

      • The nameplate saw strength in the clinical and medical skincare and color categories during the quarter.
  • Other revenue of $191 million, a $26 million decrease.
    • Represented 3.8% of net sales, down from 4.1% in the prior year period.

    • Performance driven largely by credit card revenue net which reflected the impact of higher bad debt within the portfolio.
  • Inventory turnover, on a trailing twelve-month basis, was down 2% to 2022 and up 14% to 2019.
    • Merchandise inventories were down 7% year-over-year and down 16% to 2019, reflecting ongoing disciplined inventory management.

    • The company is taking pricing actions in the second quarter to sell through remaining first-quarter seasonal merchandise inventories and May receipts at the Macy’s nameplate, and anticipates end of second-quarter merchandise inventories to be down low to mid-single digits compared to last year on a percentage basis.
  • Gross margin rate for the quarter was 40.0%, up from 39.6% in the first quarter of 2022. Versus the first quarter of 2019, gross margin rate increased 180 basis points from 38.2%.
    • Merchandise margin was flat, benefiting from lean beginning-of-year inventory levels and lower clearance markdowns, offset by promotions and category mix shifts. Compared to the first quarter of 2019, merchandise margin improved 310 basis points primarily as a result of lower markdowns and promotions.

    • Delivery expense as a percent of net sales was 40 basis points better than the prior year primarily due to improvements in our contracted carrier rates, reductions in packages per order, and a 1-percentage point decline in digital penetration year-over year. Compared to the first quarter of 2019, delivery expense as a percent of net sales was 130 bps higher primarily due to increased digital penetration and higher fuel costs.
  • Selling, general and administrative (“SG&A”) expense of $2.0 billion, a $45 million increase.
    • SG&A expense as a percent of total revenue was 37.7%, 350 basis points higher compared to the first quarter of 2022.

    • The increase in minimum wage for stores colleagues was fully implemented on May 1, 2022. The year-over-year dollar and rate growth includes the impact of these increases.

    • SG&A expense also includes continued investments in colleagues across competitive pay, incentives and benefits.

Financial Highlights

All amounts in millions except percentages and per share figures

First Quarter

 

 

2023

 

2022

Net sales

$

4,982

 

$

5,348

 

Other revenue

$

191

 

$

217

 

Comparable Sales

Owned

 

(7.9

%)

 

Owned-plus-licensed

 

(7.2

%)

 

Gross margin

$

1,994

 

$

2,117

 

Gross margin rate

 

40.0

%

 

39.6

%

Selling, general and administrative expenses

$

1,950

 

$

1,905

 

Net Income

$

155

 

$

286

 

Earnings before interest, taxes, depreciation and amortization (EBITDA)

$

466

 

$

676

 

Diluted earnings per share (EPS)

$

0.56

 

$

0.98

 

Adjusted Net income

$

157

 

$

315

 

Adjusted EBITDA

$

468

 

$

684

 

Adjusted Diluted EPS

$

0.56

 

$

1.08

 

Merchandise inventories

$

4,607

 

$

4,956

 

Dividend Declaration

On May 31, 2023, the board of directors of Macy’s, Inc. declared its regular quarterly dividend of 16.54 cents per share on Macy’s, Inc.’s common stock, payable July 3, 2023, to shareholders of record as of the close of business on June 15, 2023.

2023 Guidance

The company is taking a cautious approach to the remainder of the year and is reducing its annual 2023 sales and earnings guidance to reflect anticipated macroeconomic impacts to the consumer. On the low-end, updated guidance assumes macro pressures on the consumer worsen. The high-end assumes heightened macro pressures experienced in mid-March through April persist. Additionally, it incorporates the second quarter markdown actions the company is taking to clear out spring transitional and early summer categories to support clean end-of-quarter inventories as well as higher annual shortage rate than previously anticipated.

The company’s updated earnings guidance also includes the benefit of an incremental $200 million of cost savings identified as part of ongoing expense management that is expected to impact both gross margin and SG&A expense. The full updated outlook for 2023, presented on a 53-week basis unless otherwise noted, can be found in the presentation posted to macysinc.com/investors.

 

Guidance as of

June 1, 2023

Guidance as of

March 2, 2023

Net sales

$22.8 billion to $23.2 billion

$23.7 billion to $24.2 billion

Comparable owned-plus-licensed sales change (52 week basis)

Down 7.5% to down 6% versus 2022

Down 4% to down 2% versus 2022

Adjusted diluted earnings per share*

$2.70 – $3.20

$3.67 – $4.11

* Adjusted diluted EPS does not consider the impact of any potential future share repurchases associated with the company’s current share repurchase authorization.

The company does not provide reconciliations of the forward-looking non-GAAP measures of comparable owned plus licensed sales change and adjusted diluted earnings per share to the most directly comparable forward-looking GAAP measures because the timing and amount of excluded items are unreasonably difficult to fully and accurately estimate. For the same reasons, the company is unable to address the probable significance of the unavailable information, which could be material to future results. See Important Information Regarding Financial Measures.

Conference Call and Webcasts

A webcast of Macy’s, Inc.’s call with analysts and investors to report its first quarter of 2023 sales and earnings will be held today (June 1, 2023) at 8:00 a.m. ET. Macy’s, Inc.’s webcast, along with the associated presentation, is accessible to the media and general public via the company’s website at www.macysinc.com. Analysts and investors may call 1-877-407-0832. A replay of the conference call will be available on the company’s website or by calling 1-877-660-6853, using passcode 13737454, about three hours after the conclusion of the call. Additional information on Macy’s, Inc., including past news releases, is available at www.macysinc.com/newsroom.

Important Information Regarding Financial Measures

Please see the final pages of this news release for important information regarding the calculation of the company’s non-GAAP financial measures.

About Macy’s, Inc.

At Macy’s, Inc. (NYSE: M), we are a trusted source for quality brands at great values from off-price to luxury. Across our iconic nameplates, including Macy’s, Bloomingdale’s and Bluemercury, we help our customers express their unique style and celebrate special moments, big and small. Headquartered in New York City, we operate one of retail’s largest e-commerce businesses integrated with a nationwide footprint to deliver the most convenient and seamless shopping experience. Our purpose is tocreate a brighter future with bold representation – so we can realize the full potential of every one of us. For more information, visit macysinc.com.

Forward-Looking Statements

All statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of Macy’s management and are subject to significant risks and uncertainties. Actual results could differ materially from those expressed in or implied by the forward-looking statements contained in this release because of a variety of factors, including Macy’s ability to successfully implement its Polaris strategy, including the ability to realize the anticipated benefits within the expected time frame or at all, conditions to, or changes in the timing of proposed real estate and other transactions, prevailing interest rates and non-recurring charges, the effect of potential changes to trade policies, store closings, competitive pressures from specialty stores, general merchandise stores, off-price and discount stores, manufacturers’ outlets, the Internet and catalogs and general consumer spending levels, including the impact of the availability and level of consumer debt, possible systems failures and/or security breaches, the potential for the incurrence of charges in connection with the impairment of intangible assets, including goodwill, Macy’s reliance on foreign sources of production, including risks related to the disruption of imports by labor disputes, regional or global health pandemics, and regional political and economic conditions, the effect of weather, inflation, labor shortages, the amount and timing of future dividends and share repurchases, our ability to execute on our strategies and achieve expectations related to environmental, social, and governance matters, and other factors identified in documents filed by the company with the Securities and Exchange Commission, including under the captions “Forward-Looking Statements” and “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended January 28, 2023. Macy’s disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

MACY’S, INC.

 

Consolidated Statements of Income (Unaudited) (Note 1)

(All amounts in millions except percentages and per share figures)

 

 

13 Weeks Ended

April 29, 2023

 

13 Weeks Ended

April 30, 2022

 

$

 

% to

Net sales

 

% to

Total revenue

 

$

 

% to

Net sales

 

% to

Total revenue

Net sales

$

4,982

 

 

 

 

 

 

$

5,348

 

 

 

 

 

Other revenue (Note 2)

 

191

 

 

3.8

%

 

 

 

 

217

 

 

4.1

%

 

 

Total revenue

 

5,173

 

 

 

 

 

 

 

5,565

 

 

 

 

 

Cost of sales

 

(2,988

)

 

(60.0

%)

 

 

 

 

(3,231

)

 

(60.4

%)

 

 

Selling, general and administrative expenses

 

(1,950

)

 

 

 

(37.7

%)

 

 

(1,905

)

 

 

 

(34.2

%)

Gains on sale of real estate

 

11

 

 

 

 

0.2

%

 

 

42

 

 

 

 

0.8

%

Impairment, restructuring and other costs

 

(2

)

 

 

 

%

 

 

(8

)

 

 

 

(0.1

%)

Operating income

 

244

 

 

 

 

4.7

%

 

 

463

 

 

 

 

8.3

%

Benefit plan income, net

 

4

 

 

 

 

 

 

 

7

 

 

 

 

 

Interest expense, net

 

(37

)

 

 

 

 

 

 

(47

)

 

 

 

 

Losses on early retirement of debt

 

 

 

 

 

 

 

 

(31

)

 

 

 

 

Income before income taxes

 

211

 

 

 

 

 

 

 

392

 

 

 

 

 

Federal, state and local income tax expense (Note 3)

 

(56

)

 

 

 

 

 

 

(106

)

 

 

 

 

Net income

$

155

 

 

 

 

 

 

$

286

 

 

 

 

 

Basic earnings per share

$

0.57

 

 

 

 

 

 

$

1.01

 

 

 

 

 

Diluted earnings per share

$

0.56

 

 

 

 

 

 

$

0.98

 

 

 

 

 

Average common shares:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

273.1

 

 

 

 

 

 

 

283.6

 

 

 

 

 

Diluted

 

277.8

 

 

 

 

 

 

 

290.9

 

 

 

 

 

End of period common shares outstanding

 

272.5

 

 

 

 

 

 

 

269.7

 

 

 

 

 

Supplemental Financial Measures:

 

 

 

 

 

 

 

 

 

 

 

Gross Margin (Note 4)

$

1,994

 

 

40.0

%

 

 

 

$

2,117

 

 

39.6

%

 

 

Depreciation and amortization expense

$

218

 

 

 

 

 

 

$

206

 

 

 

 

 

MACY’S, INC.

 

Consolidated Balance Sheets (Unaudited) (Note 1)

(millions)

 

 

April 29,

2023

 

January 28,

2023

 

April 30,

2022

ASSETS:

 

 

 

 

 

Current Assets:

 

 

 

 

 

Cash and cash equivalents

$

603

 

$

862

 

$

672

Receivables

 

255

 

 

300

 

 

233

Merchandise inventories

 

4,607

 

 

4,267

 

 

4,956

Prepaid expenses and other current assets

 

390

 

 

424

 

 

372

Total Current Assets

 

5,855

 

 

5,853

 

 

6,233

Property and Equipment – net

 

5,864

 

 

5,913

 

 

5,601

Right of Use Assets

 

2,715

 

 

2,683

 

 

2,736

Goodwill

 

828

 

 

828

 

 

828

Other Intangible Assets – net

 

432

 

 

432

 

 

434

Other Assets

 

1,174

 

 

1,157

 

 

1,140

Total Assets

$

16,868

 

$

16,866

 

$

16,972

LIABILITIES AND SHAREHOLDERS’ EQUITY:

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

Merchandise accounts payable

$

2,415

 

$

2,053

 

$

2,865

Accounts payable and accrued liabilities

 

2,233

 

 

2,750

 

 

2,456

Income taxes

 

134

 

 

58

 

 

222

Total Current Liabilities

 

4,782

 

 

4,861

 

 

5,543

Long-Term Debt

 

2,996

 

 

2,996

 

 

2,994

Long-Term Lease Liabilities

 

2,996

 

 

2,963

 

 

3,030

Deferred Income Taxes

 

916

 

 

947

 

 

968

Other Liabilities

 

1,008

 

 

1,017

 

 

1,159

Shareholders’ Equity

 

4,170

 

 

4,082

 

 

3,278

Total Liabilities and Shareholders’ Equity

$

16,868

 

$

16,866

 

$

16,972

MACY’S, INC.

 

Consolidated Statements of Cash Flows (Unaudited) (Notes 1 and 5)

(millions)

 

 

13 Weeks

Ended April 29,

2023

 

13 Weeks

Ended April 30,

2022

Cash flows from operating activities:

 

 

 

Net income

$

155

 

 

$

286

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Impairment, restructuring and other costs

 

2

 

 

 

8

 

Depreciation and amortization

 

218

 

 

 

206

 

Benefit plans

 

2

 

 

 

5

 

Stock-based compensation expense

 

14

 

 

 

13

 

Gains on sale of real estate

 

(11

)

 

 

(42

)

Amortization of financing costs and premium on acquired debt

 

3

 

 

 

2

 

Deferred income taxes

 

(32

)

 

 

(17

)

Changes in assets and liabilities:

 

 

 

Decrease in receivables

 

45

 

 

 

65

 

Increase in merchandise inventories

 

(340

)

 

 

(573

)

(Increase) decrease in prepaid expenses and other current assets

 

32

 

 

 

(13

)

Increase in merchandise accounts payable

 

374

 

 

 

639

 

Decrease in accounts payable and accrued liabilities

 

(415

)

 

 

(424

)

Increase in current income taxes

 

82

 

 

 

122

 

Change in other assets and liabilities

 

(24

)

 

 

(29

)

Net cash provided by operating activities

 

105

 

 

 

248

 

Cash flows from investing activities:

 

 

 

Purchase of property and equipment

 

(215

)

 

 

(171

)

Capitalized software

 

(81

)

 

 

(90

)

Disposition of property and equipment

 

25

 

 

 

73

 

Other, net

 

1

 

 

 

(6

)

Net cash used by investing activities

 

(270

)

 

 

(194

)

Cash flows from financing activities:

 

 

 

Debt issued

 

 

 

 

850

 

Debt issuance costs

 

 

 

 

(21

)

Debt repaid

 

(1

)

 

 

(1,139

)

Debt repurchase premium and expenses

 

 

 

 

(29

)

Dividends paid

 

(45

)

 

 

(45

)

Decrease in outstanding checks

 

(13

)

 

 

(126

)

Acquisition of treasury stock

 

(35

)

 

 

(584

)

Net cash used by financing activities

 

(94

)

 

 

(1,094

)

Net decrease in cash, cash equivalents and restricted cash

 

(259

)

 

 

(1,040

)

Cash, cash equivalents and restricted cash beginning of period

 

865

 

 

 

1,715

 

Cash, cash equivalents and restricted cash end of period

$

606

 

 

$

675

 

MACY’S, INC.

 

Consolidated Financial Statements (Unaudited)

Notes:
(1) As a result of the seasonal nature of the retail business, the results of operations for the 13 weeks ended April 29, 2023 and April 30, 2022 (which do not include the Christmas season) are not necessarily indicative of such results for the fiscal year.
(2)

Other Revenue is inclusive of the following amounts due to the reclassification of Macy’s Media Network net revenue from SG&A to Other Revenue. Reclassifications were made to the prior years’ amounts to conform with the classifications of such amounts in the most recent year.

 

(millions)

13 Weeks Ended

April 29, 2023

 

13 Weeks Ended

April 30, 2022

 

$

 

% to

Net sales

 

$

 

% to

Net sales

Credit card revenues, net

$

162

 

3.3

%

 

$

191

 

3.6

%

Macy’s Media Network revenue, net

 

29

 

0.6

%

 

 

26

 

0.5

%

Other Revenue

$

191

 

3.8

%

 

$

217

 

4.1

%

 

 

 

 

 

 

 

 

Net Sales

$

4,982

 

 

 

$

5,348

 

 

 
(3)

The income tax expense of $56 million and $106 million, or 26.5% and 27.0% of pretax income, for the 13 weeks ended April 29, 2023 and April 30, 2022, respectively, reflect a different effective tax rate as compared to the company’s federal income tax statutory rate of 21%. The income tax effective rates for the 13 weeks ended April 29, 2023 and April 30, 2022 were impacted primarily by the effect of state and local taxes and the vesting and cancellations of certain stock-based compensation awards.

(4) Gross margin is defined as net sales less cost of sales.
(5) Restricted cash of $3 million has been included with cash and cash equivalents for both the 13 weeks ended April 29, 2023 and April 30, 2022.

MACY’S, INC.

Important Information Regarding Non-GAAP Financial Measures

The company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). However, management believes that certain non-GAAP financial measures provide users of the company’s financial information with additional useful information in evaluating operating performance. Management believes that providing supplemental changes in comparable sales on an owned-plus-licensed basis, which includes adjusting for the impact of comparable sales of departments licensed to third parties, assists in evaluating the company’s ability to generate sales growth, whether through owned businesses or departments licensed to third parties, and in evaluating the impact of changes in the manner in which certain departments are operated. Earnings before interest, taxes, depreciation and amortization (EBITDA) is a non-GAAP financial measure which the company believes provides meaningful information about its operational efficiency by excluding the impact of changes in tax law and structure, debt levels and capital investment. In addition, management believes that excluding certain items from EBITDA, net income and diluted earnings per share that are not associated with the company’s core operations and that may vary substantially in frequency and magnitude from period-to-period provides useful supplemental measures that assist in evaluating the company’s ability to generate earnings and to more readily compare these metrics between past and future periods.

The company does not provide reconciliations of the forward-looking non-GAAP measures of comparable owned plus licensed sales change and adjusted diluted earnings per share to the most directly comparable forward-looking GAAP measures because the timing and amount of excluded items are unreasonably difficult to fully and accurately estimate. For the same reasons, the company is unable to address the probable significance of the unavailable information, which could be material to future results. See Important Information Regarding Financial Measures.

Non-GAAP financial measures should be viewed as supplementing, and not as an alternative or substitute for, the company’s financial results prepared in accordance with GAAP. Certain of the items that may be excluded or included in non-GAAP financial measures may be significant items that could impact the company’s financial position, results of operations or cash flows and should therefore be considered in assessing the company’s actual and future financial condition and performance. Additionally, the amounts received by the company on account of sales of departments licensed to third parties are limited to commissions received on such sales. The methods used by the company to calculate its non-GAAP financial measures may differ significantly from methods used by other companies to compute similar measures. As a result, any non-GAAP financial measures presented herein may not be comparable to similar measures provided by other companies.

MACY’S, INC.

 

Important Information Regarding Non-GAAP Financial Measures

(All amounts in millions except percentages and per share figures)

 

Changes in Comparable Sales

 

Comparable Sales vs. 13 Weeks Ended April 30, 2022

 

Macy’s, Inc.

 

Macy’s

 

Bloomingdale’s

Increase (decrease) in comparable sales on an owned basis (Note 6)

(7.9

%)

 

(8.7

%)

 

(3.9

%)

Impact of departments licensed to third parties (Note 7)

0.7

%

 

0.8

%

 

(0.4

%)

Increase (decrease) in comparable sales on an owned-plus-licensed basis

(7.2

%)

 

(7.9

%)

 

(4.3

%)

Notes:

(6)

Represents the period-to-period percentage change in net sales from stores in operation for both the entire 13 weeks ended April 29, 2023 and April 30, 2022. Such calculation includes all digital sales and excludes commissions from departments licensed to third parties. Stores impacted by a natural disaster or undergoing significant expansion or shrinkage remain in the comparable sales calculation unless the store, or material portion of the store, is closed for a significant period of time. Definitions and calculations of comparable sales may differ among companies in the retail industry.

(7)

Represents the impact of including the sales of departments licensed to third parties occurring in stores in operation throughout the year presented and the immediately preceding year and all online sales in the calculation of comparable sales. Macy’s and Bloomingdale’s license third parties to operate certain departments in their stores and online and receive commissions from these third parties based on a percentage of their net sales, while Bluemercury does not participate in licensed businesses. In its financial statements prepared in conformity with GAAP, the company includes these commissions (rather than sales of the departments licensed to third parties) in its net sales. The company does not, however, include any amounts in respect of licensed department sales (or any commissions earned on such sales) in its comparable sales in accordance with GAAP (i.e., on an owned basis). The amounts of commissions earned on sales of departments licensed to third parties are not material to its net sales for the periods presented.

Non-GAAP financial measures, excluding certain items below, are reconciled to the most directly comparable GAAP measure as follows:

  • EBITDA and adjusted EBITDA are reconciled to GAAP net income.

  • Adjusted net income is reconciled to GAAP net income.

  • Adjusted diluted earnings per share is reconciled to GAAP diluted earnings per share.

EBITDA and Adjusted EBITDA

 

 

13 Weeks

Ended

April 29, 2023

 

13 Weeks

Ended

April 30, 2022

Net income

$

155

 

$

286

Interest expense, net

 

37

 

 

47

Losses on early retirement of debt

 

 

 

31

Federal, state and local income tax expense

 

56

 

 

106

Depreciation and amortization

 

218

 

 

206

EBITDA

 

466

 

 

676

Impairment, restructuring and other costs

 

2

 

 

8

Adjusted EBITDA

$

468

 

$

684

Adjusted Net Income and Adjusted Diluted Earnings Per Share

 

 

13 Weeks Ended

April 29, 2023

 

13 Weeks Ended

April 30, 2022

 

Net

Income

 

Diluted

Earnings

Per Share

 

Net

Income

 

Diluted

Earnings

Per Share

As reported

$

155

 

$

0.56

 

$

286

 

 

$

0.98

 

Impairment, restructuring and other costs

 

2

 

 

 

 

8

 

 

 

0.03

 

Losses on early retirement of debt

 

 

 

 

 

31

 

 

 

0.11

 

Income tax impact of certain items identified above

 

 

 

 

 

(10

)

 

 

(0.04

)

As adjusted to exclude certain items above

$

157

 

$

0.56

 

$

315

 

 

$

1.08

 

 

Media – Chris Grams

[email protected]

Investors – Pamela Quintiliano

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Luxury Department Stores Other Retail Catalog Bridal Fashion Jewelry Retail Footwear Online Retail

MEDIA:

Logo
Logo

Dollar General Corporation Reports First Quarter 2023 Results

Dollar General Corporation Reports First Quarter 2023 Results

Updates Financial Guidance for Fiscal Year 2023

GOODLETTSVILLE, Tenn.–(BUSINESS WIRE)–
Dollar General Corporation (NYSE: DG) today reported financial results for its fiscal 2023 first quarter (13 weeks) ended May 5, 2023.

  • Net Sales Increased 6.8%

  • Same-Store Sales Increased 1.6%

  • Operating Profit Decreased 0.7% to $740.9 Million

  • Diluted Earnings Per Share (“EPS”) Decreased 2.9% to $2.34

  • Cash Flows From Operations of $191 Million

  • Company Updates pOpshelf Real Estate Plans for Fiscal Year 2023

  • Board of Directors Declares Quarterly Cash Dividend of $0.59 per share

“While the macroeconomic environment has been more challenging than expected, particularly for our core customer, we are confident in Dollar General’s ability to deliver strong growth in the years ahead, despite the near-term pressure which impacted our first quarter sales results and is anticipated to impact our full-year sales and EPS,” said Jeff Owen, Dollar General’s chief executive officer.

“We are controlling what we can control and have made significant progress improving our execution on multiple fronts, including on our supply chain recovery efforts and enhancements to the customer experience with our previously announced investment in incremental labor hours. In addition, we executed more than 800 real estate projects, including new store openings in our larger footprint Dollar General formats, which continue to outperform our expectations, and drive higher sales productivity compared to our traditional stores.”

“Looking ahead, we feel good about our position, and are taking action to better serve our core customer, which is our most important calling at Dollar General. Overall, we remain well positioned to serve all of our customers with our unique combination of value and convenience, while also creating long-term shareholder value.”

First Quarter 2023 Highlights

Net sales increased 6.8% to $9.3 billion in the first quarter of 2023 compared to $8.8 billion in the first quarter of 2022. The net sales increase was primarily driven by positive sales contributions from new stores and growth in same-store sales, partially offset by the impact of store closures. Same-store sales increased 1.6% compared to the first quarter of 2022, driven by an increase in average transaction amount, partially offset by a decrease in customer traffic. Same-store sales in the first quarter of 2023 included growth in the consumables category, partially offset by declines in each of the seasonal, home, and apparel categories.

Gross profit as a percentage of net sales was 31.6% in the first quarter of 2023 compared to 31.3% in the first quarter of 2022, an increase of 34 basis points. This gross profit rate increase was primarily attributable to higher inventory markups, decreased transportation costs, and a decreased LIFO provision; partially offset by increased shrink, markdowns, and inventory damages, as well as a greater proportion of sales coming from the consumables category, which generally has a lower gross profit rate than other product categories.

Selling, general and administrative expenses (“SG&A”) as a percentage of net sales were 23.7% in the first quarter of 2023 compared to 22.8% in the first quarter of 2022, an increase of 94 basis points. The primary expenses that were a greater percentage of net sales in the current year period were retail labor, repairs and maintenance, and depreciation and amortization; partially offset by a decrease in incentive compensation.

Operating profit for the first quarter of 2023 decreased 0.7% to $740.9 million compared to $746.2 million in the first quarter of 2022.

Interest expense for the first quarter of 2023 increased 109.3% to $83.0 million compared to $39.7 million in the first quarter of 2022, primarily driven by higher average borrowings and higher interest rates.

The effective income tax rate in both the first quarter of 2023 and the first quarter of 2022 was 21.8%. This effective income tax rate was flat due to offsetting changes driven by a lower state effective tax rate, and less benefit from stock-based compensation in the first quarter of 2023 compared to the first quarter of 2022.

The Company reported net income of $514.4 million for the first quarter of 2023, a decrease of 6.9% compared to $552.7 million in the first quarter of 2022. Diluted EPS decreased 2.9% to $2.34 for the first quarter of 2023 compared to diluted EPS of $2.41 in the first quarter of 2022.

Merchandise Inventories

As of May 5, 2023, total merchandise inventories, at cost, were $7.3 billion compared to $6.1 billion as of April 29, 2022, an increase of 14.7% on a per-store basis. This increase primarily reflects the impact of product cost inflation.

Capital Expenditures

Total additions to property and equipment in the first quarter of 2023 were $363 million, including approximately: $153 million for improvements, upgrades, remodels and relocations of existing stores; $101 million for distribution and transportation-related projects; $90 million related to store facilities, primarily for leasehold improvements, fixtures and equipment in new stores; and $8 million for information systems upgrades and technology-related projects. During the first quarter of 2023, the Company opened 212 new stores, remodeled 582 stores, and relocated 22 stores.

Share Repurchases

In the first quarter of 2023, as planned, the Company did not repurchase any shares under its share repurchase program. The total remaining authorization for future repurchases was $1.4 billion at the end of the first quarter of 2023.

Under the program, repurchases may be made from time to time in open market transactions, including pursuant to trading plans adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, or in privately negotiated transactions. The timing, manner and number of shares repurchased will depend on a variety of factors, including price, market conditions, compliance with the covenants and restrictions under the Company’s debt agreements, cash requirements, excess debt capacity, results of operations, financial condition and other factors. The authorization has no expiration date. Information regarding the Company’s updated share repurchase expectations for 2023 can be found under “Fiscal Year 2023 Financial Guidance and Store Growth Outlook.”

Dividend

On May 30, 2023, the Company’s Board of Directors declared a quarterly cash dividend of $0.59 per share on the Company’s common stock, payable on or before July 25, 2023 to shareholders of record on July 11, 2023. While the Board of Directors currently intends to continue regular cash dividends, the declaration and amount of future dividends are subject to the sole discretion of the Board and will depend upon, among other things, the Company’s results of operations, cash requirements, financial condition, contractual restrictions, excess debt capacity, and other factors the Board may deem relevant in its sole discretion.

Fiscal Year 2023 Financial Guidance and Store Growth Outlook

The macroeconomic environment is more challenging than the Company had previously anticipated, which the Company believes is having a significant impact on customers’ spending levels and behaviors.

The Company remains confident in the business and its long-term growth prospects, but is revising its outlook for fiscal year 2023, provided on March 16, 2023, to reflect these more challenging macroeconomic headwinds, and now expects:

  • Net sales growth in the range of approximately 3.5% to 5.0%, compared to its previous expectation of 5.5% to 6%; both of which include an anticipated negative impact of approximately two percentage points due to lapping the fiscal 2022 53rd week

  • Same-store sales growth in the range of approximately 1.0% to 2.0%, compared to its previous expectation of 3.0% to 3.5%

  • Diluted EPS in the range of an approximate 8% decline to flat, compared to its previous expectation of growth of approximately 4% to 6%, both of which include an anticipated negative impact of approximately four percentage points due to lapping the fiscal 2022 53rd week

    • The updated Diluted EPS guidance includes an anticipated negative impact of approximately four percentage points due to higher interest expense in fiscal 2023, compared to the anticipated negative impact of approximately three percentage points included in the prior EPS guidance.

  • This Diluted EPS guidance assumes an effective tax rate of approximately 22.5%, compared to the previous assumption in the range of approximately 22.5% to 23.0%

  • Capital expenditures, including those related to investments in the Company’s strategic initiatives, in the range of $1.6 billion to $1.7 billion, compared to its previous expectation of $1.8 billion to $1.9 billion.

The Company’s guidance assumes no share repurchases in 2023, as compared to its previous expectation of share repurchases of approximately $500 million.

The Company is reducing the number of expected new store openings in the pOpshelf format in 2023. As a result, the Company now expects to execute 3,110 real estate projects in the United States, including 990 new store openings, 2,000 remodels, and 120 store relocations. This is compared to the previous expectation of 3,170 real estate projects in fiscal 2023, including 1,050 new store openings, 2,000 remodels, and 120 store relocations.

Conference Call Information

The Company will hold a conference call on June 1, 2023 at 9:00 a.m. CT/10:00 a.m. ET, hosted by Jeff Owen, chief executive officer, John Garratt, president, and Kelly Dilts, chief financial officer. To participate via telephone, please call (877) 407-0890 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 13738243. There will also be a live webcast of the call available at https://investor.dollargeneral.com under “News & Events, Events & Presentations.” A replay of the conference call will be available through June 29, 2023, and will be accessible via webcast replay or by calling (877) 660-6853. The conference ID for the telephonic replay is 13738243.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act. Forward-looking statements include those regarding the Company’s outlook, strategy, initiatives, plans and intentions including, but not limited to, statements made within the quotation of Mr. Owen, and in the sections entitled “Share Repurchases,” “Dividend,” and “Fiscal Year 2023 Financial Guidance and Store Growth Outlook.” A reader can identify forward-looking statements because they are not limited to historical fact or they use words such as “outlook,” “may,” “will,” “should,” “could,” “would,” “can,” “believe,” “anticipate,” “plan,” “project,” “expect,” “estimate,” “target,” “forecast,” “predict,” “position,” “assume,” “opportunities,” “intend,” “continue,” “future,” “beyond,” “ongoing,” “potential,” “long-term,” “near-term,” “guidance,” “goal,” “outcome,” “uncertainty,” “look to,” “move ahead,” “looking ahead,” “years ahead,” “subject to,” “committed,” “confident,” “focus on,” or “likely to,” and similar expressions that concern the Company’s strategies, plans, initiatives, intentions or beliefs about future occurrences or results. These matters involve risks, uncertainties and other factors that may change at any time and may cause actual results to differ materially from those which the Company expected. Many of these statements are derived from the Company’s operating budgets and forecasts as of the date of this release, which are based on many detailed assumptions that the Company believes are reasonable. However, it is very difficult to predict the effect of known factors on future results, and the Company cannot anticipate all factors that could affect future results that may be important to an investor. All forward-looking information should be evaluated in the context of these risks, uncertainties and other factors. Important factors that could cause actual results to differ materially from the expectations expressed in or implied by such forward-looking statements include, but are not limited to:

  • economic factors, including but not limited to employment levels; inflation (and the company’s ability to adjust prices sufficiently to offset the effect of inflation); pandemics (such as the COVID-19 pandemic); higher fuel, energy, healthcare and housing costs; higher interest rates, consumer debt levels, and tax rates; lack of available credit; tax law changes that negatively affect credits and refunds; decreases in, or elimination of, government stimulus programs or subsidies such as unemployment and food/nutrition assistance programs; commodity rates; transportation, lease and insurance costs; wage rates (including the heightened possibility of increased federal, state and/or local minimum wage rates); foreign exchange rate fluctuations; measures or events that create barriers to or increase the costs of international trade (including increased import duties or tariffs); impacts of failure of the U.S. government to raise the U.S. debt ceiling; and changes in laws and regulations and their effect on, as applicable, customer spending and disposable income, the company’s ability to execute its strategies and initiatives, the company’s cost of goods sold, the company’s SG&A expenses (including real estate costs), and the company’s sales and profitability;

  • failure to achieve or sustain the company’s strategies, initiatives and investments, including those relating to merchandising (including non-consumable initiatives), real estate and new store development, international expansion, store formats and concepts, digital, marketing, health services, shrink, damages, sourcing, private brand, inventory management, supply chain, private fleet, store operations, expense reduction, technology, pOpshelf, Fast Track, and DG Media Network;

  • competitive pressures and changes in the competitive environment and the geographic and product markets where the company operates, including, but not limited to, pricing, promotional activity, expanded availability of mobile, web-based and other digital technologies, and alliances or other business combinations;

  • failure to timely and cost-effectively execute the company’s real estate projects or to anticipate or successfully address the challenges imposed by the company’s expansion, including into new countries or domestic markets, states, or urban or suburban areas;

  • levels of inventory shrinkage and damages;

  • failure to successfully manage inventory balances, issues related to supply chain disruptions, seasonal buying pattern disruptions, and distribution network capacity;

  • failure to maintain the security of the company’s business, customer, employee or vendor information or to comply with privacy laws, or the company or one of its vendors falling victim to a cyberattack (which risk is heightened as a result of political uncertainty involving China and the current conflict between Russia and Ukraine) that prevents the company from operating all or a portion of its business;

  • damage or interruption to the company’s information systems as a result of external factors, staffing shortages or challenges in maintaining or updating the company’s existing technology or developing or implementing new technology;

  • a significant disruption to the company’s distribution network, the capacity of the company’s distribution centers or the timely receipt of inventory, or delays in constructing, opening or staffing new distribution centers (including temperature-controlled distribution centers);

  • risks and challenges associated with sourcing merchandise from suppliers, including, but not limited to, those related to international trade (for example, political uncertainty involving China and disruptive political events such as the current conflict between Russia and Ukraine);

  • natural disasters, unusual weather conditions (whether or not caused by climate change), pandemic outbreaks or other health crises (for example, the COVID-19 pandemic), political or civil unrest, acts of war, violence or terrorism, and disruptive global political events (for example, political uncertainty involving China and the current conflict between Russia and Ukraine);

  • product liability, product recall or other product safety or labeling claims;

  • incurrence of material uninsured losses, excessive insurance costs or accident costs;

  • failure to attract, develop and retain qualified employees while controlling labor costs (including the heightened possibility of increased federal, state and/or local minimum wage rates/salary levels) and other labor issues, including employee safety issues and employee expectations and productivity;

  • loss of key personnel or inability to hire additional qualified personnel or inability to enforce non-compete agreements that we have in place with management personnel;

  • risks associated with the Company’s private brands, including, but not limited to, the company’s level of success in improving their gross profit rate at expected levels;

  • seasonality of the company’s business;

  • failure to protect the company’s reputation;

  • the impact of changes in or noncompliance with governmental regulations and requirements, including, but not limited to, those dealing with the sale of products, including without limitation, product and food safety, marketing, labeling or pricing; information security and privacy; labor and employment; employee wages and benefits (including the heightened possibility of increased federal, state and/or local minimum wage rates/salary levels); health and safety; imports and customs; bribery; climate change; and environmental compliance, as well as tax laws (including those related to the federal, state or foreign corporate tax rate), the interpretation of existing tax laws, or the company’s failure to sustain its reporting positions negatively affecting the company’s tax rate, and developments in or outcomes of private actions, class actions, derivative actions, multi-district litigation, arbitrations, administrative proceedings, regulatory actions or other litigation or of inquiries from federal, state and local agencies, regulatory authorities, attorneys general, committees, subcommittees and members of the U.S. Congress, and other local, state, federal and international governmental authorities;

  • new accounting guidance or changes in the interpretation or application of existing guidance;

  • deterioration in market conditions, including market disruptions, adverse conditions in the financial markets including financial institution failures, limited liquidity and interest rate increases, changes in the company’s credit profile, compliance with covenants and restrictions under the company’s debt agreements, and the amount of the company’s available excess capital;

  • the factors disclosed under “Risk Factors” in the company’s most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q; and

  • such other factors as may be discussed or identified in this press release.

All forward-looking statements are qualified in their entirety by these and other cautionary statements that the Company makes from time to time in its SEC filings and public communications. The Company cannot assure the reader that it will realize the results or developments the Company anticipates or, even if substantially realized, that they will result in the consequences or affect the Company or its operations in the way the Company expects. Forward-looking statements speak only as of the date made. The Company undertakes no obligation, and specifically disclaims any duty, to update or revise any forward-looking statements as a result of new information, future events or circumstances, or otherwise, except as otherwise required by law. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included herein or that may be made elsewhere from time to time by, or on behalf of, the Company.

Investors should also be aware that while the Company does, from time to time, communicate with securities analysts and others, it is against the Company’s policy to disclose to them any material, nonpublic information or other confidential commercial information. Accordingly, shareholders should not assume that the Company agrees with any statement or report issued by any securities analyst regardless of the content of the statement or report. Furthermore, the Company has a policy against confirming projections, forecasts or opinions issued by others. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the Company’s responsibility.

About Dollar General Corporation

Dollar General Corporation (NYSE: DG) is proud to serve as America’s neighborhood general store. Founded in 1939, Dollar General lives its mission of Serving Others every day by providing access to affordable products and services for its customers, career opportunities for its employees, and literacy and education support for its hometown communities. As of May 5, 2023, the company’s 19,294 Dollar General, DG Market, DGX and pOpshelf stores across the United States and Mi Súper Dollar General stores in Mexico provide everyday essentials including food, health and wellness products, cleaning and laundry supplies, self-care and beauty items, and seasonal décor from our high-quality private brands alongside many of the world’s most trusted brands such as Coca Cola, PepsiCo/Frito-Lay, General Mills, Hershey, J.M. Smucker, Kraft, Mars, Nestlé, Procter & Gamble and Unilever.

 
 
 

DOLLAR GENERAL CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

 

 

 

 

 

 

(Unaudited)

 

 

 

 

May 5,

 

April 29,

 

February 3,

 

 

 2023 

 

 2022

 

 2023 

ASSETS
Current assets:
Cash and cash equivalents

 $

       313,064

 $

       335,613

 

 $

       381,576

Merchandise inventories

 

       7,335,845

 

       6,087,399

 

 

       6,760,733

Income taxes receivable

 

             50,863

 

             33,576

 

 

          135,775

Prepaid expenses and other current assets  

 

          355,688

 

 

          280,282

 

 

 

          302,925

Total current assets  

 

       8,055,460

 

 

       6,736,870

 

 

 

       7,581,009

Net property and equipment  

 

       5,420,134

 

 

       4,451,028

 

 

 

       5,236,309

Operating lease assets  

 

     10,726,523

 

 

     10,183,152

 

 

 

     10,670,014

Goodwill  

 

       4,338,589

 

 

       4,338,589

 

 

 

       4,338,589

Other intangible assets, net  

 

       1,199,700

 

 

       1,199,720

 

 

 

       1,199,700

Other assets, net  

 

             63,527

 

 

             46,949

 

 

 

             57,746

Total assets  

 $

29,803,933

 

 $

26,956,308

 

 

 $

29,083,367

 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term obligations

 $

                     –

 $

       900,635

 

 $

                     –

Short-term borrowings

 

          250,000

 

                        –

 

 

                        –

Current portion of operating lease liabilities

 

       1,311,753

 

       1,205,043

 

 

       1,288,939

Accounts payable

 

       3,679,170

 

       3,906,852

 

 

       3,552,991

Accrued expenses and other

 

          848,757

 

          930,260

 

 

       1,036,919

Income taxes payable

 

             10,999

 

               9,051

 

 

               8,919

Total current liabilities  

 

       6,100,679

 

 

       6,951,841

 

 

 

       5,887,768

Long-term obligations  

 

       7,028,767

 

 

       3,947,462

 

 

 

       7,009,399

Long-term operating lease liabilities  

 

       9,399,833

 

 

       8,959,174

 

 

 

       9,362,761

Deferred income taxes  

 

       1,111,434

 

 

          907,020

 

 

 

       1,060,906

Other liabilities  

 

          227,969

 

 

          229,187

 

 

 

          220,761

Total liabilities  

 

     23,868,682

 

 

     20,994,684

 

 

 

     23,541,595

 
Commitments and contingencies
 
Shareholders’ equity:
Preferred stock

 

                        –

 

                        –

 

 

                        –

Common stock

 

          191,921

 

          198,623

 

 

          191,718

Additional paid-in capital

 

       3,701,564

 

       3,606,414

 

 

       3,693,871

Retained earnings

 

       2,041,118

 

       2,157,589

 

 

       1,656,140

Accumulated other comprehensive loss

 

                  648

 

 

             (1,002

)

 

 

                     43

Total shareholders’ equity  

 

       5,935,251

 

 

       5,961,624

 

 

 

       5,541,772

Total liabilities and shareholders’ equity  

 $

29,803,933

 

 $

26,956,308

 

 

 $

29,083,367

 
 
 

DOLLAR GENERAL CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Income

(In thousands, except per share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

For the Quarter Ended

 

May 5,

 

% of Net

 

April 29,

 

% of Net

 

 2023 

 

Sales

 

 2022 

 

Sales

Net sales

 $

   9,342,832

 

100.00

%

 $

    8,751,352

 

100.00

%

Cost of goods sold

 

      6,387,358

 

68.37

 

 

 

       6,012,989

 

68.71

 

Gross profit

 

      2,955,474

 

31.63

 

 

       2,738,363

 

31.29

 

Selling, general and administrative expenses

 

      2,214,616

 

23.70

 

 

 

       1,992,206

 

22.76

 

Operating profit

 

         740,858

 

7.93

 

 

          746,157

 

8.53

 

Interest expense

 

            83,038

 

0.89

 

 

 

             39,676

 

0.45

 

Income before income taxes

 

         657,820

 

7.04

 

 

          706,481

 

8.07

 

Income tax expense

 

         143,440

 

1.54

 

 

 

          153,824

 

1.76

 

Net income

 $

      514,380

 

5.51

%

 

 $

       552,657

 

6.32

%

   
Earnings per share:        
Basic

 $

             2.35

 

 $

              2.42

 
Diluted

 $

             2.34

 

 $

              2.41

 
Weighted average shares outstanding:    
Basic

 

         219,193

 

 

          228,477

 
Diluted

 

         220,107

 

 

          229,609

 
 
 
 

DOLLAR GENERAL CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands)

 

 

 

 

 

 

 

For the 13 Weeks Ended

 

 

May 5,

 

April 29,

 

 

 

 2023

 

 

 

 2022

 

Cash flows from operating activities:
Net income

 $

          514,380

 

 $

         552,657

 

Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization

 

             201,907

 

 

            172,563

 

Deferred income taxes

 

               50,442

 

 

               81,679

 

Noncash share-based compensation

 

               25,083

 

 

 

               26,945

 

Other noncash (gains) and losses

 

               28,630

 

 

               68,585

 

Change in operating assets and liabilities:
Merchandise inventories

 

           (601,138

)

 

           (538,921

)

Prepaid expenses and other current assets

 

              (56,866

)

 

             (34,482

)

Accounts payable

 

             116,363

 

 

            172,110

 

Accrued expenses and other liabilities

 

           (176,804

)

 

           (116,384

)

Income taxes

 

               86,992

 

 

               64,814

 

Other  

 

                  2,126

 

 

 

                     (50

)

Net cash provided by (used in) operating activities  

 

             191,115

 

 

 

            449,516

 

       
Cash flows from investing activities:
Purchases of property and equipment

 

           (363,141

)

 

           (281,580

)

Proceeds from sales of property and equipment

 

                  1,539

 

 

                    736

 

Net cash provided by (used in) investing activities  

 

           (361,602

)

 

 

           (280,844

)

 
Cash flows from financing activities:
Repayments of long-term obligations

 

                (4,505

)

 

               (3,034

)

Net increase (decrease) in commercial paper outstanding

 

                  3,068

 

 

            705,300

 

Borrowings under revolving credit facilities

 

             500,000

 

 

                          –

 

Repayments of borrowings under revolving credit facilities

 

           (250,000

)

 

                          –

 

Repurchases of common stock

 

                           –

 

 

           (746,773

)

Payments of cash dividends

 

           (129,401

)

 

           (125,262

)

Other equity and related transactions

 

              (17,187

)

 

               (8,119

)

Net cash provided by (used in) financing activities  

 

             101,975

 

 

 

           (177,888

)

 
Net increase (decrease) in cash and cash equivalents

 

              (68,512

)

 

               (9,216

)

Cash and cash equivalents, beginning of period

 

             381,576

 

 

            344,829

 

Cash and cash equivalents, end of period  

 $

          313,064

 

 

 $

         335,613

 

 
Supplemental cash flow information:
Cash paid for:
Interest

 $

          145,419

 

 $

           52,349

 

Income taxes

 $

              5,992

 

 $

              7,226

 

Supplemental schedule of non-cash investing and financing activities:
Right of use assets obtained in exchange for new operating lease liabilities

 $

          386,055

 

 $

         396,628

 

Purchases of property and equipment awaiting processing for payment, included in Accounts payable

 $

          160,510

 

 $

         141,202

 

 
 
 

DOLLAR GENERAL CORPORATION AND SUBSIDIARIES

Selected Additional Information

(Unaudited)

 

 

 

 

 

 

Sales by Category (in thousands)

 

 

 

 

 

 

 

For the Quarter Ended

 

 

 

May 5,

 

April 29,

 

 

 

2023

 

2022

 

% Change

Consumables

 $

                 7,582,882

 $

                 6,960,501

 

8.9

%

Seasonal

 

                       962,681

 

                       961,378

 

0.1

%

Home products

 

                       531,189

 

                       539,822

 

-1.6

%

Apparel

 

                       266,080

 

 

                       289,651

 

-8.1

%

Net sales

 $

                 9,342,832

 

 $

                 8,751,352

 

6.8

%

 
 

 Store Activity

 

For the Quarter Ended

May 5,

April 29,

2023

 

2022

 
Beginning store count  

 

                          19,104

 

             18,130

 

New store openings  

 

                               212

 

                   239

 

Store closings  

 

                                (22

)

                    (13

)

Net new stores  

 

                               190

 

 

                   226

 

Ending store count  

 

                          19,294

 

 

             18,356

 

Total selling square footage (000’s)  

 

                       144,696

 

 

           136,466

 

Growth rate (square footage)  

 

6.0

%

 

5.8

%

 

Investor Contact:

Kevin Walker, (615) 855-4954

Media Contacts:

Jennifer Moreau, (877) 944-3477

Crystal Luce, (615) 855-5210

KEYWORDS: Tennessee United States North America

INDUSTRY KEYWORDS: Home Goods Other Retail Family Food/Beverage Consumer Discount/Variety Other Consumer Retail

MEDIA:

Logo
Logo

Constellation to Acquire Ownership Stake in Texas Nuclear Plant From NRG Energy

Constellation to Acquire Ownership Stake in Texas Nuclear Plant From NRG Energy

Company will purchase 44% share of South Texas Project Electric Generating Station, expanding nation’s largest carbon-free nuclear fleet

BALTIMORE–(BUSINESS WIRE)–
Constellation, operator of the nation’s largest fleet of reliable, carbon-free nuclear plants, announced today it is acquiring NRG Energy Inc.’s 44 percent ownership stake in the South Texas Project Electric Generating Station, a 2,645-megawatt, dual-unit nuclear plant located about 90 miles southwest of Houston. The transaction is valued at $1.75 billion, with an effective purchase price of $1.4 billion after taking into consideration the present value of tax benefits to Constellation. The transaction will be financed with a combination of cash and debt.

“The South Texas Project is an exceptionally well-maintained plant and its ability to produce resilient, carbon-free energy 24/7 makes it among the most valuable power sources in the world,” said Joe Dominguez, president and CEO of Constellation. “With the potential to run for at least 46 more years with the right policy support, we look forward to working with the South Texas Project’s other owners to continue bringing clean, reliable electricity to this growing region for decades to come.”

After the transaction, Constellation will be one of three owners with oversight of the South Texas Project Nuclear Operating Company (STPNOC), which will continue to operate the plant. The purchase is subject to approval by the Nuclear Regulatory Commission and Department of Justice. We expect the deal to be completed by year end.

One of the newest and largest nuclear plants in the U.S., the South Texas Project has an exceptional track record for safety and reliability, generating enough carbon-free power for two million average homes.

Constellation is an industry leader in operating nuclear plants safely, efficiently and reliably, with a fleetwide capacity factor of more than 94 percent over the past decade, or about 4 percent higher than the industry average. The company has ownership interests in 13 generating stations with 23 nuclear units capable of producing approximately 21,000 megawatts of electricity, enough clean energy to power approximately 15 million homes.

Constellation already has a strong and growing presence in Texas as an employer, taxpayer and significant provider of electricity and other services to the region. The company owns and operates 3,520 megawatts of natural gas-fired generation at its Colorado Bend II, Wolf Hollow II and Handley generating stations in Texas, in addition to 169 megawatts of wind energy at the Whitetail and Sendero wind projects. Constellation also is a supplier in Texas’ competitive retail energy market, supplying electricity, natural gas, energy efficiency and other services to approximately 200,000 residential and commercial customers statewide.

The company and its more than 550 Texas employees donated $460,000 to nonprofit organizations across the state in 2022 and contributed 4,800 volunteer hours. Constellation also paid $33.6 million in state and local taxes in Texas last year.

BofA Securities is serving as the exclusive financial advisor to Constellation and Sidley Austin LLP is the lead transaction counsel to the company.

About Constellation

Headquartered in Baltimore, Constellation Energy Corporation (Nasdaq: CEG) is the nation’s largest producer of clean, carbon-free energy and a leading supplier of energy products and services to businesses, homes, community aggregations and public sector customers across the continental United States, including three fourths of Fortune 100 companies. With annual output that is nearly 90% carbon-free, our hydro, wind and solar facilities paired with the nation’s largest nuclear fleet have the generating capacity to power the equivalent of 15 million homes, providing about 10% of the nation’s clean energy. We are further accelerating the nation’s transition to a carbon-free future by helping our customers reach their sustainability goals, setting our own ambitious goal of achieving 100% carbon-free generation by 2040, and by investing in promising emerging technologies to eliminate carbon emissions across all sectors of the economy. Follow Constellation on LinkedIn and Twitter.

Paul Adams

Constellation Communications

410-470-9700

[email protected]

KEYWORDS: United States North America Texas Maryland

INDUSTRY KEYWORDS: Oil/Gas Alternative Energy Energy Nuclear Utilities

MEDIA: